Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Vitiligo is one of the most visually distinct skin conditions, defined by patches of depigmented skin that can appear anywhere on the body. While it’s medically harmless, its emotional impact can be ...

Please provide your email address to receive an email when new articles are posted on . The American Skin Association has awarded grants amounting to $50 million over the past 37 years. These grants ...

People with vitiligo often need to use many medicines every day to help regain pigment in their skin and reduce other side effects. Some people may use light therapy, pills, or surgery to help reverse ...

This article is sponsored by Incyte. Vitiligo is a chronic autoimmune condition that manifests as white patches of depigmented skin, or a complete loss of color, on affected areas of the body. The ...

New study reveals higher cardiovascular risk in vitiligo patients, underscoring need for proactive care. Study: Vitiligo is associated with an increased risk of cardiovascular diseases: a large-scale, ...

TAMPA (BLOOM) – May is Mental Health Month, a time to raise awareness about the critical connection between physical and mental health. One area that often goes overlooked is the significant impact of ...